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Novel HSPB1 mutation causes both
motor neuronopathy and distal myopathy
ABSTRACT
Objective: To identify the cause of isolated distal weakness in a family with both neuropathic and
myopathic features on EMG and muscle histology.
Methods: Case study with exome sequencing in 2 affected individuals, bioinformatic prioritization
of genetic variants, and segregation analysis of the likely causal mutation. Functional studies
included Western blot analysis of the candidate protein before and after heat shock treatment
of primary skin fibroblasts.
Results: A novel HSPB1 variant (c.387C.G, p.Asp129Glu) segregated with the phenotype and
was predicted to alter the conserved a-crystallin domain common to small heat shock proteins. At
baseline, there was no difference in HSPB1 protein levels nor its binding partner aB-crystallin.
Heat shock treatment increased HSPB1 protein levels in both patient-derived and control fibro-
blasts, but the associated increase in aB-crystallin expression was greater in patient-derived than
control fibroblasts.
Conclusions: The HSPB1 variant (c.387C.G, p.Asp129Glu) is the likely cause of distal neuro-
myopathy in this pedigree with pathogenic effects mediated through binding to its partner heat
shock protein aB-crystallin. Mutations in HSBP1 classically cause a motor axonopathy, but this
family shows that the distal weakness can be both myopathic and neuropathic. The traditional
clinical classification of distal weakness into “myopathic” or “neuropathic” forms may be mislead-
ing in some instances, and future treatments need to address the pathology in both tissues. Neurol
Genet 2016;2:e110; doi: 10.1212/NXG.0000000000000110
GLOSSARY
CK 5 creatine kinase.
In the absence of other phenotypic features, the differential diagnosis of distal lower limb weakness
with atrophy can be challenging. Clinical investigations are used to distinguish primary distal myo-
pathies from a pure neurogenic disorder in an attempt to narrow down the differential diagnosis for
targeted genetic analysis. Distal hereditary motor neuropathies are genetically heterogeneous and
often overlapping with axonal forms of Charcot-Marie-Tooth disease, adding further complexity
to the diagnostic approach. Here, we describe a family with late-onset weakness of the distal lower
limbs. EMG and pathologic analysis showed evidence of both primary myopathy and motor neurop-
athy. Exome sequencing identified a novel mutation in the conserved a-crystallin domain ofHSPB1
affecting expression levels of its binding partner aB-crystallin following heat shock. The multiple
tissues involved in this disorder are important for both the clinical classification of distal weakness and
the development of new treatments.
CASE REPORT A 45-year-old man (III-1 in figure 1A) presented with difficulty descending stairs and insta-
bility when standing unsupported. He dragged his right foot and could not push off either forefoot. He had pes
cavus, wasting of all muscles below the knee, and a bilateral high steppage gait. He was unable to stand on tiptoe
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or balance on either leg. Plantar flexion was weak
(Medical Research Council grade 3), but the only
ankle movement to overcome gravity. Ankle jerks were
absent with muted plantar responses but normal sen-
sation. Routine examination findings above the knee
were normal. Serum creatine kinase (CK) was 1,060
IU/L. Other routine neuromuscular investigations
were normal. Now 66 years old, the examination
findings are unchanged and CK has normalized
(,300 IU/L). He can walk 2 miles with orthotic aids.
III-5 presented aged 56 years with bilateral calf fas-
ciculations and intrinsic foot muscle wasting. He was
unable to spread his toes. Otherwise, examination
and CK were normal. Now 64 years old, his calf
and peroneal muscles remain strong and he enjoys
aerobic exercise.
Figure 1 Pedigree, MRI, and muscle histology
(A) Pedigree of a family of Irish descent with evidence of distal neuromuscular disease in I-1, III-1, III-3, and III-5. *DNAwas available for Sanger sequencing, **DNAwas
available for whole-exome and Sanger sequencing. (B) T1 MRI of III-1 demonstrating severe fatty replacement of the muscles of the lower leg with relative sparing of
tibialis anterior (green arrows). (C) Less marked fatty replacement and (D) active high short tau inversion recovery signal abnormality of the muscles of the lower thigh,
principally affecting biceps femoris and semimembranosus (red arrowheads) but also the vasti, with relative sparing of sartorius and semitendinosus, and complete
sparing of the adductors, rectus femoris, and gracilis (green arrows). (E) Minor T1 changes in the upper thigh. Muscle histology of gastrocnemius (III-1) (F–I) and of tibialis
anterior (III-5) (J–P). (F) Hematoxylin &eosin (HE) staining demonstrating awide range of fiber diameters andgroups of small fibers, internal nucleation (G), and an increase
in endomysial and perimysial fibrous connective tissue. (H) Scattered fibers contain vacuoles without a basophilic rim. Few fibers show acute necrosis or phagocytosis,
but there is a small mononuclear cell inflammatory focus around a blood vessel (I). (J) HE staining demonstrating variation in fiber size with round atrophic fibers (K) and
a slightly increased frequency of muscle fibers with internal nuclei (L). (M) Oxidative staining with NADH shows mildly moth-eaten fibers and mild subsarcolemmal
accentuation in ring-shaped fibers. (N andO)Esterasehistochemistrywithin the insetdemonstrates angulatedand roundedatrophic fiberswith intenseesterase staining
and internal nuclei. (P) Adenosine triphosphatase (pH4.3) stainingdemonstrating fiber-typegroupingand someangulated fibers.Gastrocnemius is recognized to bemore
prone to secondary myopathic change than tibialis anterior. The following antibodies were used for muscle histochemistry: dystrophin: Dy10/12B2 (N term), Dy4/6
D3 (rod), and Dy8/6C5 (C term); associated glycoproteins: Ad1/20A6 (a-sarcoglycan), bSarc1/5B1 (b-sarcoglycan), 35DAG/21B5 (g-sarcoglycan), dSarc3/12C1
(d-sarcoglycan), and 43DAG/8D5 (b-dystroglycan); b-spectrin: RBC2/3D5 (to monitor membrane integrity on sections); laminins: commercial anti–laminin a5 (Chem-
iconMAB 1924), b1 (Chemicon MAB 1921) and g1 chain (Chemicon MAB 1920), andMer3/22B2 (equivalent to 300 kDa a2 chain fragment); caveolin 3, Emerin, and
lamin A/C: commercial antibodies (Transduction LabsC38320 andNovocastra NCL-LAM-A/C, respectively); calpain 3: Calp3d/2C4 (exon 1) andCalp3c/12A2 (exon 8);
dysferlin: NCL-hamlet (exon 53) and Ham3/17B2 (at exon 11-12 junction); and telethonin (G-11), neonatal myosin heavy chain (NCL-MHCn).
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A further brother (III-3) developed foot drop in
his fifth decade. A sister (III-8) in her sixth decade re-
mains asymptomatic. The maternal grandfather (I-1)
had foot drop and walked unsteadily by lifting his feet
high and audibly slapping them on the ground. The
mother (II-2) remained independently ambulant with
occasional cramps into her eighth decade.
Initial neurophysiologic examination of III-1 and
III-5 demonstrated reduced distal compound muscle
action potentials with normal conduction velocities,
but with greater jitter in tibialis anterior than attributable
to denervation. Ten years later, III-1 had typical myo-
pathic motor unit potentials in the legs, slowing of motor
and sensory conduction and loss of distal sensory nerve
action potentials (table e-1 at Neurology.org/ng).
Serial MRI of III-1 demonstrated early severe fatty
infiltration of all lower leg muscles with relative spar-
ing of tibialis anterior (figure 1B). Subsequently,
selective fatty replacement and edema affected the
thigh muscles (figure 1, C and D), with severity of
involvement increasing with distance from the hips
(figure 1, C and E).
Histologic examination of gastrocnemius in III-1
suggested a severe myopathy (figure 1, F–I), with
normal immunohistochemistry (table e-2), immuno-
blot, and mitochondrial complex function. Tibialis
anterior of III-5 showed histologic evidence of both
myopathic and neurogenic changes (figure 1, J–P).
The predominantly myopathic phenotype led to
candidate gene analysis of known distal myopathy genes
DES, CRYAB (encoding aB-crystallin),MYOT, LBD3,
TTN, VCP, FKRP, and GNE, which were normal.
LABORATORYMETHODS AND RESULTS Illumina
TruSeq 62 Mb exome capture sequencing (100 bp
paired-end reads, HiSeq 2000) and alignment (UCSC
hg19) was performed on DNA from III-1 and III-5.
No genetic variants known to cause similar phenotypes
were found (coverage data in table e-3). Variants
with minor allele frequency .0.01 in local and inter-
national databases were discarded. Heterozygous and
X-chromosome variants and those affecting genes
implicated in neuromuscular diseases were prioritized
bioinformatically (tables e-4 through e-8).
A novel missense mutation in HSPB1
(c.387C.G, p.Asp129Glu) was confirmed in all 3
affected brothers (III-1, III-3, and III-5) by Sanger
sequencing (table e-9 and figure e-1) and absent in
the clinically unaffected sister, III-8 (figure 2A). This
mutation lies within the characteristic, and highly
conserved a-crystallin domain of small heat shock
proteins, often implicated by HSPB1- and CRYAB-
related diseases (figure 2B).
Expression of HSPB1 and CRYAB was increased
following 1 hour of heat shock by incubation at 44°C
in both control- and patient-derived fibroblasts (fig-
ure 2C). At baseline and after heat shock, there was
no difference in HSPB1 expression between control-
and patient-derived fibroblasts. However, while
patient and control CRYAB expressions were indistin-
guishable at baseline, CRYAB expression after heat
shock was greater in patient-derived fibroblasts than
that in controls.
Standard protocol approvals, registrations, and patient
consents. This study had national ethical approval and
institutional review board approval, and patients pro-
vided informed consent.
DISCUSSION Eighteen pathogenic mutations in
HSPB1 have been previously described in patients
with a motor axonal neuropathy (collated in reference
1, original articles cited in the supplementary referen-
ces), either in isolation as a distal hereditary motor neu-
ropathy or as Charcot-Marie-Tooth 2F in the presence
Figure 2 Sequence validation, functional conservation, and Western blot data
(A) Sanger sequencing electropherograms demonstrating the segregation of the heterozygous
HSPB1 c.387C.G variant with the disease phenotype in the 4 siblings. (B) Correspondence of
the novel pathologic a-crystallin domain mutation site (in red) in human HSPB1 to human CRYAB
andHSPB1analogs in other species. Sites of known pathologicmutations are in blue. (C)Western
blot of HSPB1 and CRYAB expression in control (F152, F153, and F011) and patient-derived
fibroblasts before, and immediately after, heat shock by 1-hour incubation at 44°C.
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of clinical sensory neuron involvement. Although the
phenotype seen in the patients we described bears
some resemblance to the previously published cases,
the myopathic features are unusual. This is important
because initial clinical presentation in our family, with
CK over 1,000 IU/L and muscle histology indicated
a predominantly myopathic process, pointed toward
a genetically determined distal myopathy, and the
differential diagnosis did not include mutations in
HSPB1. Targeted sequencing of genes previously
known to cause a distal myopathy did not identify the
underlying cause, which was only revealed through
whole-exome sequencing.
TheHSPB1 (c.387C.G) variant is highly likely
to be responsible for the disorder in the family we
describe here because (1) it was not present in
healthy controls (not present in Exome Aggrega-
tion Consortium or Single Nucleotide Polymor-
phism Database); (2) it segregated with the
phenotype; (3) it is predicted to disrupt a highly
conserved amino acid residue within the a-crystal-
lin domain of HSBP1 (p.Asp129Glu), a region of
the protein containing other pathogenic muta-
tions; and (4) the variant increased CRYAB expres-
sion in response to heat shock.
HSPB1 and aB-crystallin are both stress-inducible,
adenosine triphosphate–independent small heat shock
proteins expressed in skeletal muscle and neurons, which
interact to form large hetero-oligomers. HSPB1 enhan-
ces the stability of aB-crystallin,2 which is the better
chaperone.3 Heterozygous aB-crystallin p.Asp109His,4
p.Arg120Gly,5 and other6,7 mutations have been asso-
ciated with the accumulation of aB-crystallin in pa-
tients with similar distal myopathic features to the
family we describe here. It is also interesting that a sim-
ilar pattern of muscle and nerve involvement was
recently reported in 2 families with distal weakness
caused by mutation in the related protein encoded by
HSPB8.8
Disruption of the interaction between Asp109 and
Arg120 during aB-crystallin homodimerization is pre-
dicted to be important in causing a myopathy.4 The
HSPB1 p.Asp129Glu and aB-crystallin p.Asp109His
substitutions correspond to the same a-crystallin
domain aspartate residue (figure 2B). Thus, the ele-
vated CK seen in our family may result from
an alteration in the analogous aspartate-arginine
interaction during HSPB1–aB-crystallin hetero-
dimerization, leading to the accumulation of
aB-crystallin on heat shock. This pathologic model
predicts that primary myopathic features may also be
present in individuals with the HSPB1 p.Arg140Gly
substitution,9 equivalent to aB-crystallin p.Arg120Gly
and with similar physicochemical consequences.10
Intriguingly, the presence of the aB-crystallin p.
Asp109His variant has been shown sufficient to
increase the accumulation of aB-crystallin and the
rate of apoptosis in transfected HeLa cells via mech-
anisms mitigated by wild-type HSPB1.11 Should the
HSPB1 p.Asp129Glu substitution compromise these
roles of HSPB1, then any aB-crystallin accumulation
and related apoptosis could proceed unchecked,
independently of any defective heteroligomeric
a-crystallin domain interaction.
In exome studies, it is tempting to overlook hetero-
zygous mutations in genes not previously linked to the
phenotype because many are rare or private polymor-
phisms. However, a broader consideration of the
underlying disease mechanisms, and particularly the
relevance of key interacting proteins, will assist in the
prioritization of novel variants for further functional
studies. This will help establish pathogenicity and
broadening our understanding of the relationship
between genotype and phenotype. A deeper knowl-
edge of the cell types involved in widely expressed
genes is critical for the development of novel therapies.
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